热门资讯> 正文
萨雷普塔任命迈克尔·塞韦里诺为首席执行官
2026-07-27 20:40
- Sarepta Therapeutics (SRPT) has appointed Michael Severino as chief executive officer, effective July 28, 2026.
- Severino, the former CEO of Tessera Therapeutics, will also join Sarepta's board of directors. He succeeds Doug Ingram, who is retiring and will remain with the company in an advisory role through the end of 2026 to support the leadership transition
- Severino brings more than 25 years of biopharmaceutical industry experience, including serving as vice chairman and president of AbbVie, where he oversaw research and development as well as the company's corporate strategy office.
- SRPT shares rose 7% premarket to $16.7.
More on Sarepta Therapeutics
- Sarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly Stance
- Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
- Sarepta reiterates $1.2B-$1.4B 2026 net product revenue guidance while targeting Cohort 8 data by year-end
- Sarepta turns negative despite Q1 beats; 2026 guidance maintained
推荐文章
港股异动 | 创新药概念部分走高，先声药业涨逾3.5%，斩获罗氏15亿美元授权大单；再鼎医药涨逾4.5%
华盛早报 | 美伊互轰深夜升级！美油劲升6%重回90美元；高盛、美银等21家大行拟明年发行稳定币；戴尔盘后升8%，Q2净利暴增逾两倍
美股前瞻 | 抛售潮席卷全球债市！纳指期货跌逾1%，黄金失守4400美元；黄仁勋、马斯克今日齐聚G20科技部长会议；Anthropic拿下350亿美元算力大单
一图看懂 | 蔚来Q2净亏超5亿！营收321亿同比大增近7成，整车毛利率升至18.5%；CEO李斌豪言Q3交付冲刺11万
华盛早报 | 沃什刚“放鹰”，特朗普转头称加息“荒谬”！智谱上半年API收入飙升27倍；百度双重主要上市今起生效
9月1日外盘头条：俄美财长在G20会议期间罕见会晤 FTC起诉亚马逊 微软Outlook和ChatGPT Work出现用户宕机
美股前瞻 | 苹果换帅！库克明日正式卸任；美伊互袭，油价急涨4%！三大期指齐挫；SK海力士被曝考虑英特尔代工
港股异动 | 半导体股部分走高，壁仞科技涨近8%，上半年营收暴增近2000%；长光辰芯涨逾6.5%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
